Ellington Management Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Ellington Management Group’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,350	Closed	-$170K	–	1097
2017 Q4	$170K	Buy	1,350 +320	+31%	+$41K	0.03%	513
2017 Q3	$141K	Buy	+1,030	New	+$138K	0.02%	567
2016 Q1	–	Sell	-1,325	Closed	-$266K	–	778
2015 Q4	$266K	Buy	+1,325	New	+$264K	0.09%	326

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Ellington Management Group's TTPH Position: Q1 2018 in Review

Ellington Management Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 1,350 shares — an estimated $170K sold.

Ellington Management Group first reported a position in TTPH in Q4 2015 and held it in 3 quarters. The position peaked at $266K in Q4 2015. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

Ellington Management Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Ellington Management Group sold 1,350 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $170K.
Ellington Management Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 3 quarters.
Ellington Management Group's Tetraphase Pharmaceuticals, Inc. position peaked at $266K in Q4 2015.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Ellington Management Group's 13F filing for Q1 2018, filed 15 May 2018.